Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Brooklyn ImmunoTherapeutics, Inc.
  6. Financials
    BTX   US1140821000

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
0.5701 USD   +2.57%
08/11BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/11Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
08/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2021 2022 2023 2024
Capitalization1 21732,8--
Enterprise Value (EV)1 21732,832,832,8
P/E ratio -1,48x-1,08x-1,08x-0,98x
Yield ----
Capitalization / Revenue ----
EV / Revenue ----
EV / EBITDA ----
Price to Book ----
Nbr of stocks (in thousands) 52 04457 469--
Reference price (USD) 4,170,570,570,57
Announcement Date 04/15/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2021 2022 2023 2024
Net sales1 ----
EBITDA ----
Operating profit (EBIT)1 -114-27,7-28,8-31,6
Operating Margin ----
Pre-Tax Profit (EBT)1 -122-27,7-28,8-31,6
Net income1 -122-27,7-28,8-31,6
Net margin ----
EPS2 -2,82-0,53-0,53-0,58
Dividend per Share ----
Announcement Date 04/15/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 -----
EBITDA -----
Operating profit (EBIT)1 -9,11-6,30-13,9-7,20-7,48
Operating Margin -----
Pre-Tax Profit (EBT)1 -8,46-9,38-3,41-7,20-7,48
Net income1 -8,48-9,38-3,41-7,20-7,48
Net margin -----
EPS2 --0,17-0,06-0,14-0,14
Dividend per Share -----
Announcement Date 04/15/202207/01/202208/11/2022--
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Fiscal Period: December 2021 2022 2023 2024
Net Debt ----
Net Cash position ----
Leverage (Debt / EBITDA) ----
Free Cash Flow1 --21,2-22,0-24,3
ROE (Net Profit / Equities) ----
Shareholders' equity1 ----
ROA (Net Profit / Asset) ----
Assets1 ----
Book Value Per Share ----
Cash Flow per Share ----
Capex ----
Capex / Sales ----
Announcement Date 04/15/2022---
1 USD in Million
Estimates
Key data
Capitalization (USD) 32 762 847
Number of employees 10
Free-Float 73,4%
Free-Float capitalization (USD) 24 050 206
Avg. Exchange 20 sessions (USD) 285 735
Average Daily Capital Traded 0,87%
EPS & Dividend